We performed western blots using the D1694 antibody targeting the N-terminal region of DYRK1A (named after α-DYRK1A-Nter) and we observed decreased levels of the full-length form of DYRK1A (DYRK1AFL, 90 kDa) associated to an increase of the truncated form (DYRK1AT, 50 kDa) in the hippocampus of AD patients (Additional file 1: Figure 1F). The gene discussed is DYRK1A; the disease is Alzheimer disease.